Your browser doesn't support javascript.
loading
Development of advanced conduction disturbances following balloon-expandable transcatheter aortic valve replacement leads to poorer clinical outcomes.
Ashraf, Hasan; Fortuin, Floyd D; Sweeney, John; DeValeria, Patrick A; Lanza, Louis A; Ramsay, Gary; Maranzano, Pedro; Patrick, Lorna; Scott, Luis R.
Afiliação
  • Ashraf H; Department of Cardiovascular Medicine Mayo Clinic Phoenix AZ USA.
  • Fortuin FD; Department of Cardiovascular Medicine Mayo Clinic Phoenix AZ USA.
  • Sweeney J; Department of Cardiovascular Medicine Mayo Clinic Phoenix AZ USA.
  • DeValeria PA; Department of Cardiovascular Surgery Mayo Clinic Phoenix AZ USA.
  • Lanza LA; Department of Cardiovascular Surgery Mayo Clinic Phoenix AZ USA.
  • Ramsay G; Department of Cardiovascular Medicine Mayo Clinic Phoenix AZ USA.
  • Maranzano P; Department of Cardiovascular Medicine Mayo Clinic Phoenix AZ USA.
  • Patrick L; Department of Cardiovascular Medicine Mayo Clinic Phoenix AZ USA.
  • Scott LR; Department of Cardiovascular Medicine Mayo Clinic Phoenix AZ USA.
J Arrhythm ; 36(4): 755-761, 2020 Aug.
Article em En | MEDLINE | ID: mdl-32782650
ABSTRACT

BACKGROUND:

Transcatheter aortic valve replacement (TAVR) is a reliable method of treating patients with severe aortic stenosis, but is associated with postprocedure conduction defects.

OBJECTIVE:

The purpose of this study was to compare clinical outcomes in patients who developed advanced conduction defects post-TAVR to those who did not.

METHODS:

We conducted a retrospective chart review of 243 patients who underwent balloon-expandable TAVR with the Edwards Sapien valve to determine the incidence of advanced conduction defects in our cohort. We compared clinical outcomes including overall mortality, improvement in symptomatology, and improvement in left ventricular ejection fraction.

RESULTS:

Among the 243 patients included in the study, 9.1% (22/243) required permanent pacemaker (PPM); 19.8% (48/243) developed left bundle branch block (LBBB), and 71.2% (173/243) did not develop any permanent advanced conduction defects. Overall 1-year mortality was similar across all three groups. There was significant improvement in New York Heart Association functional capacity of all groups post-TAVR, but this was much less in the PPM group (45.5% vs 68.8%, P = .04). Postprocedure from TAVR, patients with LBBB or PM were less likely to have improvement in their ejection fraction (net loss of -0.7% for LBBB and -5.7% for PPM compared to a net gain of 2.3% for no-LBBB/PM (P = .02).

CONCLUSION:

Patients who develop LBBB or require PM post-TAVR with Edwards Sapien valves are less likely to improve New York Heart Association functional capacity and more likely to have no improvement or deterioration of their pre-TAVR left ventricular ejection fraction.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Arrhythm Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Arrhythm Ano de publicação: 2020 Tipo de documento: Article